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Abstract
There is established clinical evidence for differences in drug response, cure rates and survival 
outcomes between different ethnic populations, but the causes are poorly understood. Differences 
in frequencies of functional genetic variants in key drug response and metabolism genes may 
significantly influence drug response differences in different populations. To assess this, we 
genotyped 1330 individuals of African (n = 372) and European (n = 958) descent for 4535 single-
nucleotide polymorphisms in 350 key drug absorption, distribution, metabolism, elimination and 
toxicity genes. Important and remarkable differences in the distribution of genetic variants were 
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observed between Africans and Europeans and among the African populations. These could 
translate into significant differences in drug efficacy and safety profiles, and also in the required 
dose to achieve the desired therapeutic effect in different populations. Our data points to the need 
for population-specific genetic variation in personalizing medicine and care.
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INTRODUCTION
Drug response, cure rates and survival outcomes for many diseases have improved 
significantly over the last few decades, but not all populations have benefited equally from 
this progress. In particular, there is growing clinical evidence concerning differences in the 
incidence of adverse drug reactions (ADRs) by population.1 ADRs represent the fourth 
leading cause of morbidity and mortality in developed countries, with direct medical costs of 
US$137–177 billion annually in the USA alone.2–4 The cost and contribution of ADRs to 
patient morbidity, hospitalization and mortality in African countries are not known.
Several observations have pointed to the fact that African and Hispanic populations are 
generally at increased susceptibility to ADRs, and have poorer survival and response rates 
for many diseases and medications when compared with European and Asian populations.5,6 
For example, the rate of cisplatin-related toxicity has been shown to be significantly higher 
amongst African Americans compared with western Europeans (47.6% vs 8.3%, P=0.007)7 
The maximum tolerable dose of cisplatin is 40% lower in the South African Black 
population compared with western countries (25 vs 40 mg m−2 per week).8 The risk and 
frequency of cardiotoxicity and congestive heart failure (CHF) after anthracycline treatment 
has been reported to be significantly higher in African compared with European populations 
(1.7-fold greater relative risk and 7% vs 2.4% frequency, P<0.027, odds ratio = 2.93).9,10 
African ancestry has also been associated with increased likelihood of anthracycline dose 
reduction, early termination of treatment and decreased survival rates when compared with 
Europeans.11 African populations also have poorer survival and response rates,12 and 
experience significantly more frequent hematologic toxicities of leukopenia and anemia 
when compared with Europeans (P<0.006) after treatment with 5-fluorouracil (5-FU).13
The causes of these differences are poorly understood but could be due to genetic, clinical 
and/or environmental factors. The recent identification of the genetic basis of drug response 
and ADRs for many agents now makes it possible to identify the genetic causes of drug 
response differences at a population level. In the current study, we tested the hypothesis that 
the differences in frequencies of genetic variants in key genes involved in drug 
biotransformation may underlie these differences in ADR rates and response to therapy by 
population. Studies on pharmacogenomic diversity in African populations are 
underrepresented in published genomic and pharmacogenomic research and this study 
begins to address this deficiency.14–15
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MATERIALS AND METHODS
Study population
Our study population (n = 1330) consisted of individuals of African (n = 372) and European 
(n = 958) descent. Individuals of African ancestry were drawn from indigenous ethnically, 
geographically, linguistically and culturally diverse African populations originating from 
Eastern (Kenya and Tanzania), Central (Cameroon and Chad), Western (Nigeria), Saharan 
(Sudan),14 and Southern (South Africa) Africa, recruited via field expeditions (Table 1). 
Europeans were from North America (Canada) recruited via the Canadian 
Pharmacogenomics Network for Drug Safety, a multicenter active drug surveillance and 
pharmcogenomics consortium.17 All genetic ancestries were self-reported and verified by 
principal component analysis. All participants were verified for cryptic relatedness using 
identity by descent estimation, and no duplicates (>99% identity) or related individuals (86–
98% identity) were found.
This study was approved by the ethics committees of the universities and institutions 
participating in the scientific projects of the Canadian Pharmacogenomics Network for Drug 
Safety and the ethics committee of the University of Pennsylvania. Written informed 
consent was obtained from all participants or from the parents or legal guardians in case of 
minors in accordance with the Helsinki Declaration as revised in 2008 (http://
www.wma.net/en/30publications/10policies/b3/index.html, accessed 4 March 2013).
Pharmacogenomic assay design and variant clinical annotation
Our assay was designed to genotype for 4535 single-nucleotide polymorphisms (SNPs) in 
350 key genes involved in drug biotransformation, drug response and ADRs, and included 
transporters, enzymes, receptors, ion channels, transcription factors and drug targets. The 
candidate genes were selected based on their physiological roles in drug absorption, 
distribution, metabolism, elimination and toxicity. Genetic variations in the absorption, 
distribution, metabolism, elimination and toxicity genotyping panel were selected to have 
the maximum set of informative markers to assay the candidate genes. Tagging SNPs were 
selected by IdSelect algorithm,18 using data from the International HapMap consortium.19 
Functional SNPs were identified via publicly available databases (PharmGKB, HuGENet, 
ALFRED) and also from published information about their role in protein structure and/or 
function. Clinical annotations were curated from PharmGKB,20 Hiv-
pharmacogenomics.org,21 and published studies22–26
Genotyping and quality control
Genomic DNA was extracted from blood, saliva or buccal swab samples using the QIAamp 
DNA purification system (Qiagen, Toronto, Ontario, Canada) and quantified by Quant-iT 
PicoGreen assay (Invitrogen, Eugene, OR, USA), according to the manufacturer’s protocols. 
A total of 1330 DNA samples were genotyped using a customized Illumina GoldenGate 
SNP genotyping assay (Illumina, San Diego, CA, USA). Genotypes were called with the 
Illumina Genome Studio software package (Illumina). All samples in the study cohort were 
used to determine cluster boundaries in order to maximize clustering accuracy. The clusters 
were then evaluated using automated scripts, while the ambiguous ones were evaluated 
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manually. Twenty samples and 326 SNPs with call rates below 90% were excluded from the 
analyses (average call rate for included samples = 95.0% and SNPs = 99.8%). Quality 
control analysis was performed by date of genotyping and by plate to check for systematic 
errors in the generated data set. No systematic errors were found. After quality control, 1310 
samples and 4209 SNPs remained for further analyses.
Statistical analyses
Statistical analyses were performed using SVS/HelixTree 7.6.8 (Golden Helix, Bozeman, 
MT, USA). Fisher’s exact test was used for comparing allele frequencies among populations 
and an ANOVA F-test was used to explore the pharmacogenomic diversity in African 
populations. The type-I error rate of 0.05 was used as a significance threshold after 
Bonferroni correction for 4209 tests.
RESULTS
Pharmacogenomic diversity and population ancestry
Distribution of pharmacogenomic polymorphisms—We compared allele 
frequencies between African and European populations (Supplementary Table 1). Several 
variants in the cytochrome P4503A (CYP3A) family showed the most significant differences 
and were more frequent in African compared with European populations: CYP3A rs4646450 
−90.34% vs 16.77%, P=6.93E-274; CYP3A4 rs2740574 −66.25% vs 3.25%, P=3.95E-257; 
CYP3A4 rs2242480 −77.59% vs 11.14%, P=2.92E-231; CYP3A4 rs4646437 − 77.73% vs 
11.45%, P=1.43E-229; CYP3A5 rs776746 − 74.37% vs 10.13%, P=3.60E-221; and CYP3A 
rs6945984 − 76.89% vs 12.72%, P = 3.52E-212 (Table 2). Striking differences were also 
observed for other cytochrome P450 variants and variants in solute carrier and ATP-binding 
cassette transporters.
Most ADR-associated risk variants or variants associated with poor response or shortened 
survival rates were more frequent in African populations compared with Europeans 
(Supplementary Table 2). Specific examples of clinically important differences between 
African and European populations focusing on cancer, antiretroviral and antimicrobial 
pharmacogenomics are provided here, while other examples can be found in the 
Supplementary Material of this manuscript (Supplementary Tables 1–2).
Pharmacogenomic diversity in cancer therapy
Anthracyclines and related substances—UGT1A6 rs17863783, ABCC2 rs8187694, 
ABCC2 rs8187710, ABCB1 rs2235047 and ABCC1 rs4148350 have been associated with the 
risk of anthracycline-induced cardiotoxicity (ACT) and CHF,22,23 while RAC2 rs13058338, 
SULT2B1 rs10426377, CBR1 rs9024 and HNMT rs17645700 have been shown to have a 
protective effect.22,23 Also, ABCB1 rs2032582 has been clinically linked to improved 
survival and response rates,26 while CYP2B6 rs3745274 has been associated with decreased 
tolerance and survival.27 The distributions of these variants were significantly different 
between African and European populations (Table 3). UGT1A6 rs17863783 (12.04% vs 
2.78%, P=9.75E-15), ABCC2 rs8187694 (14.29% vs 5.37%, P=2.54E-09), ABCC2 
rs8187710 (22.99% vs 5.47%, P = 8.87E-31), ABCB1 rs2235047 (18.21% vs 2.52%, 
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P=3.84E-36), ABCC1 rs4148350 (13.48% vs 5.43%, P=2.09E-07), RAC2 rs13058338 
(10.92% vs 24.97%, P=.09E-12), SULT2B1 rs10426377 (17.51% vs 27.39%, P= 4.66E-04), 
CBR1 rs9024 (1.40% vs 12.46%, P=1.73E-19), HNMT rs17645700 (4.76 vs 20.17, 
P=4.57E-22), ABCB1 rs2032582 (3.78% vs 45.10%, P=1.87E-106) and CYP2B6 rs3745274 
(77.73% vs 24.97%, P=4.34E-131). Variants associated with increased risk of ACT and 
CHF and decreased tolerance and survival were more frequent in African populations, while 
those associated with protection against ACT and CHF and improved survival and response 
rates were less frequent.
Cisplatin and platinum compounds—COMT rs9332377 has been associated with 
increased risk of cisplatin-induced hearing loss,28 MTR rs1805087 associated with reduced 
risk of cisplatin-induced toxicity, XRCC1 rs25487 associated with decreased risk of severe 
neutropenia when treated with platinum compounds (cisplatin, carboplatin, oxaliplatin and 
platinum)29 and MTHFR rs1801133 clinically linked to increased response to platinum 
compounds.30 The allele frequencies of these pharmacogenomic variants were significantly 
different between African and European populations (Table 4). COMT rs9332377 (32.68% 
vs 16.82%, P=5.40E-14), XRCC1 rs25487 (14.85% vs 35.07%, P=.37E-22), MTR 
rs1805087 (0.27.17 vs 18.68, P=.0142) and MTHFR rs1801133 (6.86% vs 34.77%, P=.
57E-51). Pharmacogenomic variants associated with increased risk of toxicity related to 
platinum compounds were more common in African populations, while variants associated 
with decreased risk were less common. Also, variants associated with improved response to 
platinum compounds were less frequent in African populations.
Fluororuracil—The majority of 5-FU-induced toxicity are related to the deficiency of 
dihydropyrimidine dehydrogenase, an enzyme, which metabolizes 5-FU. The common 
mutations in the dihydropyrimidine dehydrogenase gene—DPYD (DPYD rs1801265 and 
DPYD rs2297595) have been associated with fluoropyrimidine-related toxicity in cancer 
patients,31,32 while MTHFR rs1801133 has been linked to improved survival and response 
rates.33 The distributions of these mutations were different in African and European 
populations (Table 5). DPYD rs1801265 −48.88% vs 22.19%, P=4.46E-35; DPYD 
rs2297595 −19.75% vs 10.19%, P=1.30E-06; MTHFR rs1801133 −6.86% vs 34.77%, 
P=2.57E-51. Pharmacogenomic variants associated with increased risk of 5-FU-induced 
toxicity were more frequent in African populations, while MTHFR rs1801133 associated 
with improved response was less frequent.
Vincristine—Vincristine is a metabolic substrate for CYP3A5. It has been shown that 
increased risk of vincristine-induced neurotoxicity is associated with low CYP3A5 
expression.34 Therefore, mutations in CYP3A5 may influence the efficacy and toxicity of 
vincristine. We explored the distribution of CYP3A5 mutations in African and European 
populations. Strikingly significant differences were observed for the following CYP3A5 
polymorphisms: CYP3A5 rs776746 −74.37% vs 10.13%, P=3.60E-221; CYP3A5 
rs10224569 − 28%.37% vs 0.0%, P=2.39E-121; CYP3A5 rs10264272 −22.33% vs 0.32%, 
P=2.44E-83; CYP3A5 rs10249369 − 21.91% vs 0.58%, P=1.02E-75; CYP3A5 rs41303343 − 
7.56% vs 0.10% P=2.59E-25; CYP3A5 rs6956305 −9.10% vs 4.41%, P=0.0443)—Table 6. 
Also, significant differences were observed for MTHFR rs1801133 (34.77% vs 6.86%, 
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P=2.57E-51) and NOS rs1799983 (33.80% vs 4.95%, P=8.47E-012) that have been 
associated with other vincristine-related toxicities.35,36 CYP3A5 polymorphisms were more 
frequent in African compared with European populations. In contrast, ADR-associated 
variants and ABCB1*13 (3.78% vs 45.10% P=1.87E-106) that has been associated with 
efficacy26 were less frequent in African populations.
Pharmacogenomic diversity in antiretroviral and antimycobacterial therapy—
CYP2B6 rs28399499 is associated with Nevirapine-induced hepatotoxicity.21 CYP2B6 
rs3745274 is associated with rifampicin-induced liver injury and with efavirenz-induced 
lowered HDL levels, hepatotoxicity, neurotoxicity, fatigue and sleep disorders and early 
termination of treatment.21 Also, ABCC2 rs717620, ABCC2 rs17222723 and ABCC4 
rs1751034 are associated with Tenofovir-induced proximal tubulopathy and kidney tubular 
dysfunction and APOE rs429358 associated with extreme hypertriglyceridemia.20,21 The 
allele frequencies of these variants were significantly higher in the African compared with 
European populations (CYP2B6 rs28399499 − 5.20% vs 0.052%, P=7.04E-17; CYP2B6 
rs3745274 −77.73% vs 24.97%, P=4.34E-131; ABCC2 rs717620 −19.77% vs 3.24%, 
P=4.54E-28; ABCC2 rs17222723 − 14.29% vs 5.46%, P=5.94E-09; ABCC4 rs1751034 
−30.95% vs 17.79%, P=4.77E-09; APOE rs429358 −24.86% vs 13.27%, P=5.75E-08 
−Table 7), which would be compatible with increased frequency of ADRs with these drugs.
Pharmacogenomic diversity among African populations
We characterized and compared allele frequencies in five different African populations 
(Supplementary Tables 3–5). The F-statistics and P-values revealed high pharmacogenomic 
diversity among African populations. The most clinically relevant diversity was observed 
for VKORC1 rs7294 (P=8.93E-21), which is associated with warfarin dosage requirement37 
(Table 8). Other top clinically annotated variations include VKORC1 rs8050894 
(P=8.92E-07) for warfarin dosage38 and several cytochrome P450 variants associated with 
response to immunosuppressive drugs (CYP2B6 rs2279343 - P=.46E-20 for 
cyclophosphamide-induced mucositis,39 CYP2B6 rs8192709 - P=.0167 for 
cyclophosphamide-induced hemorr-hagic cystitis39 and CYP3A5 rs776746 - P=.14E-09 for 
cyclospo-rine dosage requirements20).
Pharmacogenetic variant frequencies including the frequencies of the CYP enzymes were 
observed to be remarkably variable within African populations as demonstrated by the 
following examples (Table 9 and Supplementary Table 3):
Antharcycline—The UGT1A6*4 haplotype associated with the risk of ACT and clinical 
heart failure was more frequent among Saharan (18.4%), Southern (12.9%) and Eastern 
(12.8%) Africans compared with Central (9.9%) and Western (8.8%) Africans.
Cisplatin—COMT rs9332377, which is associated with increased risk of cisplatin-induced 
hearing loss, was less common among Western (20.6%) and Saharan (23.7%) Africans 
compared with Eastern (35.2%), Southern (33.0%) and Central (32.3%) Africans.
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Antiretroviral therapy—ABCC4 rs1751034 is associated with Tenofovir-induced 
proximal tubulopathy and kidney tubular dysfunction. This variant is very frequent among 
Western Africans (44.1%), intermediate among Central (32.5%), Eastern (30.5%) and 
Southern (29.2%) Africans, and comparatively less frequent in Saharan Africans (23.7%). 
Also, CYP2B6 rs28399499, which is associated with Nevirapine-induced hepatotoxicity is 
rare among Saharan (0.0%), Central (1.2%) and Western (2.9%) Africans, and relatively 
more common in Southern (8.0%) and Eastern (6.7%) Africans.
DISCUSSION
In this manuscript, we have chosen to focus on antineoplastic, antiretroviral and 
antimycobacterial commonly used drugs from the WHO Model List of Essential Medicines. 
Cancer, HIV/AIDS and tuberculosis and their associated ADRs are major public health 
problems and have become the primary focus in health-care. In general, a higher frequency 
of genetic variants conferring increased risk to ADRs for different and commonly used 
antineoplastic, antiretroviral and antituberculosis drugs was evident in African populations.
Anthracyclines are a group of very efficacious chemotherapeutic agents and have been part 
of the backbone of therapy worldwide including Africa for the treatment of many cancers 
including leukemia, lymphoma, sarcomas, Wilms’ tumor, hepato-blastoma, and uterine, 
ovarian, lung and breast cancers. They are used to treat over 70% of all childhood 
malignancies, as well as 50–90% of breast cancer patients each year.40 Their clinical utility 
is primarily limited by a highly individually variable, cumulative dose-dependent, cardiac 
toxicity, manifesting as asymptomatic cardiac dysfunction in up to 57% of treated 
patients41,42 and restrictive or dilated cardiomyopathy resulting in CHF in up to 16% of 
treated patients.43 African populations are more sensitive to ACT and CHF when compared 
with Europeans (1.7-fold greater relative risk; frequency −7% vs 2.4%, P<0.027, odds ratio 
= 2.93).9,10 The enrichment of genetic risk factors for ACT and CHF such as UGT1A6 
rs17863783, ABCC2 rs8187694, ABCC2 rs8187710, ABCB1 rs2235047 and ABCC1 
rs4148350, in African populations suggests that these genetic differences may partially 
account for the increased sensitivity to ACT and CHF in African populations. Also, the 
enrichment of pharmacogenetic factors such as CYP2B6 rs3745274 associated with poor 
drug tolerance and poor survival rates27 could contribute to the reported increased likelihood 
of dose reduction, early termination of treatment and decreased survival rates in African 
populations.11
Cisplatin, carboplatin and oxaliplatin are all platinum compounds that have excellent 
antineoplastic properties. Cisplatin is the drug of choice for solid tumors including 
hepatoblastoma, osteosarcoma, neuroblastoma and ovarian, central nervous system, 
testicular, cervical, lung, bladder, head and neck tumors.44 Major complications include 
ototoxicity, nephrotoxicity, neurotoxicity and myelotoxicity. Irreversible hearing loss 
(ototoxicity) occurs in 10–25% of treated adults, 50% of patients treated with high doses 
(>400mgm−2) and 41–61% of treated children45–47 Cisplatin-related toxicity is more 
frequent in African populations when compared with the European population (47.6% vs 
8.3%, P = 0.007)7 Also, the maximum tolerable dose is 40% lower in African populations 
(25 vs 40 mg m−2 per week).8 In the current study, an overrepresentation of COMT 
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rs9332377 (32.58% vs 16.82%) variants associated with increased risk of hearing loss28 and 
a depletion of XRCC1 rs25487 (14.85% vs 35.07%) associated with protection against 
cisplatin-induced neutropenia,29 in African populations, was evident. This correlates with 
the reported increased frequency of cisplatin-induced toxicity in these populations and 
suggests that these differences in allele frequency may contribute to the increased ADR rates 
in these populations.
5-FU is a very effective drug commonly used in the treatment of advanced stage colon 
cancer and several other types of cancer including, breast, esophageal and stomach cancers. 
About 30% of 5-FU-treated patients suffer from severe and sometimes deadly toxicity 
including hematologic toxicities of leukopenia and anemia, myelosuppression, diarrhea, 
nausea, vomiting, mucositis and dermatitis.1 Poorer survival and decreased response rates,12 
and more frequent toxicities have been reported in African Americans when compared with 
Europeans (P<0.006).13 An enrichment of risk factors for dihydropyrimidine dehydrogenase 
deficiency such as the DPYD variants (rs1801265 −48.88% vs 22.19% and rs2297595 − 
19.75% vs 10.19%) and a decrease in the frequency of MTHFR rs1801133 (6.9% vs 34.8%) 
linked to increased therapeutic response was evident33 in Africans compared with 
Europeans. These genetic findings could at least partially explain differences in ADR rates 
and drug responsiveness between these two populations.
Vincristine is a commonly prescribed vinca alkaloid and is used in the treatment of both 
hematological and solid malignancies. In the US alone, vincristine is used to treat over 50% 
of all childhood cancers and ~30 000 adults cancer patients.34 Vincristine-induced 
neurotoxicity has been found in 34.8% of Europeans vs 4.8% of African Americans (P = 
0.007). Europeans have been shown to have a higher average grade of neurotoxicity (2.72 vs 
1, P<0.0001) and require dose reduction (4% vs 0.1%, P<0.0001) and dose omission (1.2% 
vs 0.1%, P<0.01) when compared with African populations.48 The biotransformation of 
vincristine is CYP3A5-dependent.1 The current study found an increased frequency of 
CYP3A5 polymorphisms in African populations, which correlates with the reported 
increased in the expression of CYP3A5 in these populations when compared with Europeans 
(10–30% vs 60–70%).1,49–51 Increased CYP3A5 expression would increase the clearance of 
vincristine, thus lowering the concentration of the drug in the body and decrease the risk of 
vincristine-related toxicity in African populations. This could possibly be a mechanism by 
which African populations are protected from vincristine-related toxicity.
African populations experience more frequent antiretroviral and antimycobacterial drug-
induced toxicities compared with Europeans. The incidence of nevirapine-induced 
hepatotoxicity is 17% among South Africans Blacks compared with 1–10% in Europeans, 
while 10% of Africans discontinue efavirenz therapy because of persistent toxicity 
compared with only 3% of Europeans.52 Also, 69% of Africans compared with 50% of 
European patients experience neurotoxicity after initiation of efavirenz therapy.52 This 
correlates with an overrepresentation of pharmacogenetic risk variants such as ABCC2 
rs717620, ABCC2 rs17222723, ABCC4 rs1751034, CYP2B6 rs28399499, CYP2B6 
rs3745274, APOE rs429358 and CYP2B6 rs3745274 in Africans compared with Europeans 
as observed in the current study. CYP2B6 rs3745274 is also associated with rifampicin-
induced liver injury, an important drug used in antituberculous therapy.20,21 Even though 
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differences in the incidence between Africans and Europeans are currently not known, this 
result indicates the possibility of such differences, which should be investigated in the 
future.
Overall, CYP3A variants showed the most significant differences and were more frequent in 
Africans compared with Europeans. CYP3A enzymes are involved in the metabolism of 
~40–60% of all drugs.53 Their expression varies significantly by population, with increased 
expression of CYP3A5 in particular reported in African compared with European 
populations (10%–30% of Europeans vs 60%–70% of Africans).49–51 This observation is 
consistent with the observed dramatic enrichment of CYP3A5 variants in African compared 
with European populations in the current study. Renbarger has postulated that CYP3A5 gene 
region could explain most of the drug response differences by population.48 Other striking 
differences were observed with ATP-binding cassette and solute carrier transporters, 
indicating the additional contribution of other genes. In general, we observed an enrichment 
of genetic variants, which could underlie an enhanced predisposition to several ADRs and 
poor response rates in Africans compared with Europeans.
The current study also observed important differences among the African populations, 
which could translate to significant differences in drug efficacy and safety profiles, and also 
in the dose required to achieve the desired therapeutic effect in different African 
populations. This is consistent with the reported highly variable distribution of ABCB1, 
VKORC1 and CYP enzymes among African populations.54,55 This pharmacogenomic 
heterogeneity across different ethnic groups and geographical regions within African 
populations highlights the challenge faced by regulatory agencies in African countries when 
assessing new drug applications especially when there is minimal or no data from local 
clinical trials. Therefore, an important area of focus for improving drug distribution and 
access in African populations is the development and effective use of pharmacovigilance 
systems to monitor drug response in treated patients in order to avoid, in particular, serious 
and permanently disabling ADRs. Also, local trials to assess the frequency of ADRs will be 
important.
The current study places emphasis on the importance of including different populations in 
the development of biomarkers for pharmacogenetic testing, clinical practice guidelines, and 
clinical trials. To the best of our knowledge, it is the largest study of pharmacokinetic and 
pharmcodynamic genetic markers to dissect the pharmacogenomic variation at the level of 
individual populations and the first to have included such a large number of individuals 
recruited from different indigenous African populations. This study clearly demonstrates 
that clinical trials and safety studies, which are typically done in European populations, 
cannot be extrapolated to African populations. Furthermore, it also highlights the 
compounded challenge of population heterogeneity with respect to the delivery of health-
care services in Canada and the USA. This type of study can inform clinical practice and 
clinical trials and is imperative for tailoring therapy towards individual populations. Our 
study population is not the complete representative sample of all African and European 
populations, but points to the need for local studies of genetic variants contributing to ADRs 
within all populations.
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We have shown that there are important differences in the distribution of genetic variants in 
key drug biotransformation genes by population. These could translate to significant 
differences in drug response and toxicity rates. African populations have a pharmacogenetic 
enrichment to ADR susceptibility when compared with Europeans, which could explain the 
increased susceptibility and conferring poorer survival and response rates in these 
populations. This observation highlights the need for further investment in active drug 
surveillance systems, which should be central to all health-care systems to ensure each 
patient achieves maximal therapeutic benefit and minimal toxicity. Even though studies of 
pharmacogenomic differences among populations predicts the existence of drug response 
differences by populations, some of which have already being elucidated, a prospective 
evaluation of the relationship between pharmacogenomic diversity and drug response 
variability will be warranted to validate these findings. As population diversity, especially in 
Canada and the USA continues to increase, the need for information on population-specific 
genetic variation for the implementation of personalized medicine will become more 
important.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
ACKNOWLEDGEMENTS
We acknowledged the participation of all those who took part in this study from the different Africa countries and 
Canada. We also acknowledge the contributions of Bill Beggs and other members of the Tishkoff Lab (University 
of Pennsylvania) and the Canadian Pharmacogenomics Network for Drug Safety consortium (University of British 
Columbia) for the enrolment of the study participants and for the handling of the samples, assays and records. This 
work was supported by the Canadian Institutes of Health Research, Child and Family Research Institute (Bertram 
Hoffmeister Postdoctoral Fellowship Award for Folefac Aminkeng), Canada Foundation for Innovation, Genome 
British Columbia. Additional funding was provided by Child & Family Research Institute (Vancouver, BC), 
Faculty of Medicine of the University of British Columbia, The Canadian Gene Cure Foundation and C17 Research 
Network and Childhood Cancer Foundation-Candlelighters Canada, as well as NSF (BCS-0827436) and NIH 
(R01GM076637, 8 DP1 ES022577-04) grants to S.A.T.
REFERENCES
1. O’Donnell PH, Dolan ME. Cancer pharmacoethnicity: ethnic differences in susceptibility to the 
effects of chemotherapy. Clin Cancer Res. 2009; 15:4806–4814. [PubMed: 19622575] 
2. Phillips KA, Veenstra D, Van Bebber S, Sakowski J. An introduction to cost-effectiveness and cost-
benefit analysis of pharmacogenomics. Pharmacogenomics. 2003; 4:231–239. [PubMed: 12718713] 
3. Ernst FR, Grizzle AJ. Drug-related morbidity and mortality: updating the cost-of-illness model. J 
Am Pharm Assoc (Wash). 2001; 41:192–199. [PubMed: 11297331] 
4. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a 
meta-analysis of prospective studies. JAMA. 1998; 279:1200–1205. [PubMed: 9555760] 
5. Yang JJ, Cheng C, Devidas M, Cao X, Fan Y, Campana D, et al. Ancestry and pharmacogenomics 
of relapse in acute lymphoblastic leukemia. Nat Genet. 2011; 43:237–241. [PubMed: 21297632] 
6. Kadan-Lottick NS, Ness KK, Bhatia S, Gurney JG. Survival variability by race and ethnicity in 
childhood acute lymphoblastic leukemia. JAMA. 2003; 290:2008–2014. [PubMed: 14559954] 
7. Shord SS, Thompson DM, Krempl GA, Hanigan MH. Effect of concurrent medications on cisplatin-
induced nephrotoxicity in patients with head and neck cancer. Anti-cancer drugs. 2006; 17:207–
215. [PubMed: 16428940] 
Aminkeng et al. Page 10
Pharmacogenomics J. Author manuscript; available in PMC 2015 December 18.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
8. Nyongesa C, Ruff P, Donde B, Kotzen J. A phase I study of concurrent cisplatin chemotherapy in 
patients with carcinoma of the cervix receiving pelvic radiotherapy. Int J Gynecol Cancer. 2006; 
16:1614–1619. [PubMed: 16884375] 
9. Krischer JP, Epstein S, Cuthbertson DD, Goorin AM, Epstein ML, Lipshultz SE. Clinical 
cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology 
Group experience. J Clin Oncol. 1997; 15:1544–1552. [PubMed: 9193351] 
10. Hasan S, Dinh K, Lombardo F, Kark J. Doxorubicin cardiotoxicity in African Americans. J Natl 
Med Assoc. 2004; 96:196–199. [PubMed: 14977278] 
11. Hershman D, McBride R, Jacobson JS, Lamerato L, Roberts K, Grann VR, et al. Racial disparities 
in treatment and survival among women with early-stage breast cancer. J Clin Oncol. 2005; 
23:6639–6646. [PubMed: 16170171] 
12. Polite BN, Dignam JJ, Olopade OI. Colorectal cancer model of health disparities: understanding 
mortality differences in minority populations. J Clin Oncol. 2006; 24:2179–2187. [PubMed: 
16682737] 
13. McCollum AD, Catalano PJ, Haller DG, Mayer RJ, Macdonald JS, Benson AB 3rd, et al. 
Outcomes and toxicity in african-american and caucasian patients in a randomized adjuvant 
chemotherapy trial for colon cancer. J Natl Cancer Inst. 2002; 94:1160–1167. [PubMed: 
12165641] 
14. Tishkoff SA, Reed FA, Friedlaender FR, Ehret C, Ranciaro A, Froment A, et al. The genetic 
structure and history of Africans and African Americans. Science. 2009; 324:1035–1044. 
[PubMed: 19407144] 
15. Campbell MC, Tishkoff SA. African genetic diversity: implications for human demographic 
history, modern human origins, and complex disease mapping. Ann Rev Genomics Hum Genet. 
2008; 9:403–433. [PubMed: 18593304] 
16. Lachance J, Vernot B, Elbers CC, Ferwerda B, Froment A, Bodo JM, et al. Evolutionary history 
and adaptation from high-coverage whole-genome sequences of diverse african hunter-gatherers. 
Cell. 2012; 150:457–469. [PubMed: 22840920] 
17. Carleton B, Poole R, Smith M, Leeder J, Ghannadan R, Ross C, et al. Adverse drug reaction active 
surveillance: developing a national network in Canada’s children’s hospitals. Pharmacoepidemiol 
Drug Saf. 2009; 18:713–721. [PubMed: 19507171] 
18. Carlson CS, Eberle MA, Rieder MJ, Yi Q, Kruglyak L, Nickerson DA. Selecting a maximally 
informative set of single-nucleotide polymorphisms for association analyses using linkage 
disequilibrium. Am J Hum Genet. 2004; 74:106–120. [PubMed: 14681826] 
19. International HapMap Consortium. A haplotype map of the human genome. Nature. 2005; 
437:1299–1320. [PubMed: 16255080] 
20. PharmGKB. [Accessed 10th of December 2012] The Pharmacogenomics Knowledgebase 
(PharmGKB) is a comprehensive resource that curates knowledge about the impact of genetic 
variation on drug response for clinicians and researchers. http://www.pharmgkborg.
21. [Accessed 10 December, 2012] HIV-pharmacogenomics.org. http://www.hiv-
pharmacogenomics.org.
22. Visscher H, Ross CJ, Rassekh SR, Barhdadi A, Dube MP, Al-Saloos H, et al. Phar-macogenomic 
prediction of anthracycline-induced cardiotoxicity in children. J Clin Oncol. 2012; 30:1422–1428. 
[PubMed: 21900104] 
23. Wojnowski L, Kulle B, Schirmer M, Schluter G, Schmidt A, Rosenberger A, et al. NAD(P)H 
oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-
induced cardiotoxicity. Circulation. 2005; 112:3754–3762. [PubMed: 16330681] 
24. Blanco JG, Sun CL, Landier W, Chen L, Esparza-Duran D, Leisenring W, et al. Anthracycline-
related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase 
genes--a report from the Children’s Oncology Group. J Clin Oncol. 2012; 30:1415–1421. 
[PubMed: 22124095] 
25. Blanco JG, Leisenring WM, Gonzalez-Covarrubias VM, Kawashima TI, Davies SM, Relling MV, 
et al. Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone 
oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart 
failure after childhood cancer. Cancer. 2008; 112:2789–2795. [PubMed: 18457324] 
Aminkeng et al. Page 11
Pharmacogenomics J. Author manuscript; available in PMC 2015 December 18.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
26. Maggini V, Buda G, Martino A, Presciuttini S, Galimberti S, Orciuolo E, et al. MDR1 diplotypes 
as prognostic markers in multiple myeloma. Pharmacogenet Genomics. 2008; 18:383–389. 
[PubMed: 18408561] 
27. Bray J, Sludden J, Griffin MJ, Cole M, Verrill M, Jamieson D, et al. Influence of 
pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and 
cyclophosphamide. British J Cancer. 2010; 102:1003–1009.
28. Ross CJ, Katzov-Eckert H, Dube MP, Brooks B, Rassekh SR, Barhdadi A, et al. Genetic variants 
in TPMT and COMT are associated with hearing loss in children receiving cisplatin 
chemotherapy. Nat Genet. 2009; 41:1345–1349. [PubMed: 19898482] 
29. Khrunin AV, Moisseev A, Gorbunova V, Limborska S. Genetic polymorphisms and the efficacy 
and toxicity of cisplatin-based chemotherapy in ovarian cancer patients. Pharmacogenomics J. 
2010; 10:54–61. [PubMed: 19786980] 
30. Cui LH, Yu Z, Zhang TT, Shin MH, Kim HN, Choi JS. Influence of polymorphisms in MTHFR 
677 C-->T, TYMS 3R-->2R and MTR 2756 A-->G on NSCLC risk and response to platinum-
based chemotherapy in advanced NSCLC. Pharmaco-genomics. 2011; 12:797–808.
31. Van Kuilenburg AB, Vreken P, Abeling NG, Bakker HD, Meinsma R, Van Lenthe H, et al. 
Genotype and phenotype in patients with dihydropyrimidine dehy-drogenase deficiency. Human 
Genetics. 1999; 104:1–9. [PubMed: 10071185] 
32. Gross E, Busse B, Riemenschneider M, Neubauer S, Seck K, Klein HG, et al. Strong association of 
a common dihydropyrimidine dehydrogenase gene polymorphism with fluoropyrimidine-related 
toxicity in cancer patients. PLoS One. 2008; 3:e4003. [PubMed: 19104657] 
33. Etienne-Grimaldi MC, Milano G, Maindrault-Goebel F, Chibaudel B, Formento JL, Francoual M, 
et al. Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response 
in colorectal cancer patients. Br J Clin Pharmacol. 2010; 69:58–66. [PubMed: 20078613] 
34. Egbelakin A, Ferguson MJ, MacGill EA, Lehmann AS, Topletz AR, Quinney SK, et al. Increased 
risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children 
with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2011; 56:361–367. [PubMed: 
21225912] 
35. Patino-Garcia A, Zalacain M, Marrodan L, San-Julian M, Sierrasesumaga L. Methotrexate in 
pediatric osteosarcoma: response and toxicity in relation to genetic polymorphisms and 
dihydrofolate reductase and reduced folate carrier 1 expression. J Pediatr. 2009; 154:688–693. 
[PubMed: 19159907] 
36. Krajinovic M, Robaey P, Chiasson S, Lemieux-Blanchard E, Rouillard M, Primeau M, et al. 
Polymorphisms of genes controlling homocysteine levels and IQ score following the treatment for 
childhood ALL. Pharmacogenomics. 2005; 6:293–302. [PubMed: 16013960] 
37. Shrif NE, Won HH, Lee ST, Park JH, Kim KK, Kim MJ, et al. Evaluation of the effects of 
VKORC1 polymorphisms and haplotypes, CYP2C9 genotypes, and clinical factors on warfarin 
response in Sudanese patients. Eur J Clin Pharmacol. 2011; 67:1119–1130. [PubMed: 21590310] 
38. Geisen C, Watzka M, Sittinger K, Steffens M, Daugela L, Seifried E, et al. VKORC1 haplotypes 
and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation. 
Thromb Haemost. 2005; 94:773–779. [PubMed: 16270629] 
39. Rocha V, Porcher R, Fernandes JF, Filion A, Bittencourt H, Silva W Jr, et al. Association of drug 
metabolism gene polymorphisms with toxicities, graft-versus-host disease and survival after HLA-
identical sibling hematopoietic stem cell transplantation for patients with leukemia. Leukemia. 
2009; 23:545–556. [PubMed: 19005482] 
40. Kremer LC, Caron HN. Anthracycline cardiotoxicity in children. N Engl J Med. 2004; 351:120–
121. [PubMed: 15247351] 
41. Kremer LC, van der Pal HJ, Offringa M, van Dalen EC, Voute PA. Frequency and risk factors of 
subclinical cardiotoxicity after anthracycline therapy in children: a systematic review. Ann Oncol. 
2002; 13:819–829. [PubMed: 12123328] 
42. van der Pal HJ, van Dalen EC, Hauptmann M, Kok WE, Caron HN, van den Bos C, et al. Cardiac 
function in 5-year survivors of childhood cancer: a long-term follow-up study. Arch Intern Med. 
170:1247–1255. [PubMed: 20660845] 
Aminkeng et al. Page 12
Pharmacogenomics J. Author manuscript; available in PMC 2015 December 18.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
43. Kremer LC, van Dalen EC, Offringa M, Voute PA. Frequency and risk factors of anthracycline-
induced clinical heart failure in children: a systematic review. Ann Oncol. 2002; 13:503–512. 
[PubMed: 12056699] 
44. McKeage MJ. Comparative adverse effect profiles of platinum drugs. Drug Saf. 1995; 13:228–244. 
[PubMed: 8573296] 
45. Coradini PP, Cigana L, Selistre SG, Rosito LS, Brunetto AL. Ototoxicity from cisplatin therapy in 
childhood cancer. J Pediatr Hematol Oncol. 2007; 29:355–360. [PubMed: 17551394] 
46. Kushner BH, Budnick A, Kramer K, Modak S, Cheung NK. Ototoxicity from high-dose use of 
platinum compounds in patients with neuroblastoma. Cancer. 2006; 107:417–422. [PubMed: 
16779793] 
47. Knight KR, Kraemer DF, Neuwelt EA. Ototoxicity in children receiving platinum chemotherapy: 
underestimating a commonly occurring toxicity that may influence academic and social 
development. J Clin Oncol. 2005; 23:8588–8596. [PubMed: 16314621] 
48. Renbarger JL, McCammack KC, Rouse CE, Hall SD. Effect of race on vincristine-associated 
neurotoxicity in pediatric acute lymphoblastic leukemia patients. Pediatr Blood Cancer. 2008; 
50:769–771. [PubMed: 18085684] 
49. Wrighton SA, Brian WR, Sari MA, Iwasaki M, Guengerich FP, Raucy JL, et al. Studies on the 
expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Mol 
Pharmacol. 1990; 38:207–213. [PubMed: 2385232] 
50. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, et al. Sequence diversity in CYP3A 
promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat 
Genet. 2001; 27:383–391. [PubMed: 11279519] 
51. Lee SJ, Usmani KA, Chanas B, Ghanayem B, Xi T, Hodgson E, et al. Genetic findings and 
functional studies of human CYP3A5 single nucleotide polymorphisms in different ethnic groups. 
Pharmacogenetics. 2003; 13:461–472. [PubMed: 12893984] 
52. Subbaraman R, Chaguturu SK, Mayer KH, Flanigan TP, Kumarasamy N. Adverse effects of highly 
active antiretroviral therapy in developing countries. Clin Infect Dis. 2007; 45:1093–1101. 
[PubMed: 17879931] 
53. Vazquez MA. Southwestern Internal Medicine Conference. New advances in immunosuppression 
therapy for renal transplantation. Am J Med Sci. 1997; 314:415–435. [PubMed: 9413350] 
54. Dandara C, Lombard Z, Du Plooy I, McLellan T, Norris SA, Ramsay M. Genetic variants in CYP 
(−1A2, −2C9, −2C19, −3A4 and −3A5), VKORC1 and ABCB1 genes in a black South African 
population: a window into diversity. Pharmacogenomics. 2011; 12:1663–1670. [PubMed: 
22118051] 
55. Sistonen J, Fuselli S, Palo JU, Chauhan N, Padh H, Sajantila A. Pharmacogenetic variation at 
CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scales. Pharmacogenet 
Genomics. 2009; 19:170–179. [PubMed: 19151603] 
56. Evans WE. Pharmacogenetics of thiopurine S-methyltransferase and thiopurine therapy. Ther Drug 
Monit. 2004; 26:186–191. [PubMed: 15228163] 
57. Krynetski EY, Schuetz JD, Galpin AJ, Pui CH, Relling MV, Evans WE. A single point mutation 
leading to loss of catalytic activity in human thiopurine S-methyl-transferase. Proc Natl Acad Sci 
USA. 1995; 92:949–953. [PubMed: 7862671] 
APPENDIX
THE CANADIAN PHARMACOGENOMICS NETWORK FOR DRUG SAFETY 
CONSORTIUM
The Canadian Pharmacogenomics Network for Drug Safety Consortium (Participants are 
arranged geographically by institution across Canada)—Vancouver, BC, Children’s 
Hospital, Child & Family Research Institute, CMMT, POPi: Michael Hayden, Bruce 
Carleton, Colin Ross, Stuart MacLeod, Wyeth Wasserman, Craig Mitton, Anne Smith, 
Claudette Hildebrand, Lucila Castro Pastrana, Reza Ghannadan, Rod Rassekh, Jonathan 
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Lim, Fudan Miao, Henk Visscher, Kusala Pussegoda, Folefac Aminkeng, Michelle 
Higginson, Nasim Massah,Mojgan Yazdanpanah, Johanne Sistonen, Ricardo Jimenez, 
Adrienne Borrie, Ursula Amstutz, Shevaun Hughes, Kaitlyn Shaw; Calgary, Alberta 
Children’s Hospital: Cheri Nijssen-Jordan, David Johnson, Linda Verbeek, Rick 
Kaczowka, Patti Stevenson, Andrea Hurton; Edmonton, Stollery Children’s Hospital: 
Paul Grundy, Kent Stobart, Bev Wilson, Sunil Desai, Maria Spavor, Linda Churcher, 
Terence Chow; Winnipeg, Winnipeg Children’s Hospital: Kevin Hall, Nick Honcharik, 
Sara Israels, Shanna Chan, Byron Garnham, Michelle Staub; London, London Health 
Sciences Centre: Michael Rieder, Becky Malkin; Hamilton, McMaster Children’s 
Hospital: Carol Portwine, Amy Cranston; Toronto, Hospital for Sick Children: Gideon 
Koren, Shinya Ito, Paul Nathan, Mark Greenberg, Facundo Garcia Bournissen, Miho Inoue, 
Sachi Sakaguchi, Toshihiro Tanaka, Hisaki Fujii, Mina Ogawa, Ryoko Ingram, Taro 
Kamiya & Smita Karande; Kingston, Kingston General Hospital: Mariana Silva, 
Stephanie Willing; Ottawa, Children’s Hospital of Eastern Ontario: Régis Vaillancourt, 
Pat Elliott-Miller, Donna Johnston, Herpreet Mankoo, Elaine Wong, Brenda Wilson, Lauren 
O’Connor; Health Canada: Maurica Maher; Montreal, Hospital Sainte-Justine: Jean-
Francois Bussie`res, Denis Lebel, Pierre Barret, Aure´lie Closon, Eve Coulson; Montreal 
Heart Institute: Marie-Pierre Dube´, Michael Phillips; McGill University Health Centre-
Montreal Children’s Hospital: Nada Jabado, Anelise Espirito Santo, Martine Nagy; 
McGill University: Denise Avard; Halifax, IWK Health Centre: Margaret Murray, 
Darlene Boliver, Marilyn Tiller and Carolanne Osborne.
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